Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.

Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) secured FDA approval for Eylea HD – a higher-dose of its treatment for Macular Degeneration on Monday. Jim Cramer is bullish on Regeneron stock Shares of the biotech giant responded with an over 3.0% gain this morning.

Cramer dubs Regeneron stock a ‘favourite' after two new FDA approvals

"I think it's going to be worth more," Jim Cramer said Monday after Regeneron got good news from the FDA on its macular degeneration treatment.

This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher

Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.

Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms

A quicker-than-expected U.S. approval for Regeneron Pharmaceuticals' high-dose eye disease drug, Eylea, should help return the blockbuster treatment back to growth in the next few years, Wall Street analysts said.

Regeneron's Eylea could return to growth after nod to high-dose version- analysts

Regeneron Pharmaceuticals (NASDAQ:REGN) shares moved higher in pre-market trading after the biotechnology company reported on Friday that a higher dose of its eye disorder drug EYLEA has been approved by the Food and Drug Administration (FDA). The FDA approved EYLEA HD (aflibercept) Injection 8 mg for patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR).

Regeneron Pharmaceuticals shares rise on FDA approval of higher dose of eye disorder drug EYLEA

Shares of Regeneron Pharmaceuticals Inc. REGN, +1.97% gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had approved a higher-dose formulation of its macular degeneration treatment Eylea. The eight-milligram Eylea injection, jointly developed by Regeneron and Bayer AG BAYRY, -1.36%, is approved for treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, Regeneron said in a release.

Regeneron shares climb after FDA approval of macular degeneration treatment

Regeneron Pharmaceuticals has delivered market-beating results for shareholders over the prior 10 years. With competition heating up, however, the biotech may be entering a period of slowing growth.

Is Regeneron Pharmaceuticals Still a Top Growth Stock?

Regeneron reported strong Q2 2023 financial results, with an 11% YoY revenue surge to $3.2B, outperforming expectations. The FDA approved high-dose Eylea (8 mg), offering less frequent treatment, addressing prior third-party filler concerns and bolstering outlook. I recommend upgrading Regeneron's stock from 'Hold' to 'Buy', given the strong financials, promising drug developments, and recent FDA approval.

Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rating Upgrade)

The U.S. Food and Drug Administration approved the 8-mg dose of Regeneron Pharmaceuticals' eye disease drug Eylea, the company said in a statement on Friday.

US FDA approves Regeneron's 8-mg dose of eye disease drug Eylea

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Regeneron Pharmaceuticals Inc. REGN, +0.55% said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a rare and life-threatening hereditary immune disease. The treatment, Veopoz, is the first to be approved for the condition, which can cause the body to attack normal cells and damage blood and lymph vessels in the upper digestive tract.

Regeneron gets FDA green light on first treatment for life-threatening immune disease

Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.

Regeneron's (REGN) Application for Blood Cancer Drug Accepted

The U.S. health regulator on Friday approved Regeneron Pharmaceuticals' drug to treat a rare blood disease, the company said.

US FDA approves Regeneron's ultra-rare blood disease drug

CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms

Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease

TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The EMA previously granted odronextamab Orphan Drug Designation for FL and DLBCL. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Exelixis

Vertex Pharmaceuticals

iShares Nasdaq Biotechnology ETF

The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.

3 Strong Biotech Performers To Watch As Sector Nears Breakout

Adobe

Intuit

This stock screener identified 26 stocks that mutual funds are adding. We highlight seven familiar names with several in buy zones.

IBD Screen Includes Meta, Tesla, Other Big Techs, But These Others Are In Buy Zones

IQVIA Hlds

Eli Lilly

West Pharmaceutical Services

Zoetis

For investors, tracking the stocks that are up in what has otherwise been a grim year for drugmakers can help identify trends in the market.

In a Tough Year for Pharma, These 6 Stocks Are Shining

Arch Resources

BHP Billiton

Livent Corp

Tenaris S.A.

Taiwan Semiconductor Manufacturing

Encore Wire

While several market ideas have blossomed this year, many are overpriced, which naturally draws eyes to the best value stocks to buy. Here, we're talking about publicly traded securities that trade at a lower price relative to fundamental metrics, most commonly sales or earnings.

The 7 Best Value Stocks to Buy in August

Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.

Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies

Alkermes

Regeneron Pharmaceuticals' big arbitration win should help it this year. Alkermes is splitting off its oncology therapies segment into a new company.

3 Top Biotech Stocks Defying the Bear Market

Decibel Therapeautics

Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline.

Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals

Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This deal has Regeneron Pharmaceuticals agreeing to acquire Decibel Therapeutics for $4 per share in cash.

Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal

Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be a knock-out bid for the tiny drug developer. The deal values Decibel Therapeutics, which is working on treatments aimed at enhancing and restoring hearing and balance, at $109 million.

News for Regeneron Pharmaceuticals Stock (REGN)